Larimar Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Bala-Cynwyd PA United States (2016)
Status: Acquired by Zafgen, Inc. (2019)

Organization Overview

First Clinical Trial
2019
NCT04176991
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chondrial Therapeutics, Inc. | Larimar Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Larimar Therapeutics (0) Acquired (1)

beloranib (8 trials)

Drugs in Phase 2 Trials (2)

Key: Larimar Therapeutics (0) Acquired (2)

cti-1601 (3 trials)

zgn-1061 (1 trial)

Drugs in Phase 1 Trials (1)

Key: Larimar Therapeutics (0) Acquired (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 1)

Cerebellar Ataxia (Phase 1)

Friedreich Ataxia (Phase 1)

Overview

  • Highest Phase: None
  • # of Trials: 12
  • # of Trial APIs: 4